Alliance Global Partners analyst James Molloy upgraded BioCardia (BCDA) to Buy from Neutral with a $6 price target The company recently announced multiple clinical updates regarding its lead CardiAMP cell therapy platform BCDA-01, which has completed the last patient follow-up and should report final 24-month data in Q1, the analyst tells investors in a research note. The firm cites potential positive upcoming catalysts in Q1 and the stock’s “low current valuation” for the upgrade.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCDA:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue